Skip to main content

Alzheimer’s Disease- Biogen (ENGAGE/EMERGE)

The primary objective of this study is to slow cognitive and functional impairment in participants with early Alzheimer’s disease.

Phase: 3

Age: 50 to 85 years of age

Indication: Mild Cognitive Impairment due to Alzheimer’s disease

Category: Disease Modifying

For more information:

Studies Currently Available At

Sign Up For This Study